Vyleesi (Bremelanotide) in Girls Under 12: Caregiver Administration Guidance

The Direct Answer: Vyleesi Is Not for Children Under 12

Bremelanotide (Vyleesi) has no approved, studied, or clinically appropriate use in girls under 12 years of age. Full stop. The FDA label for bremelanotide restricts use to premenopausal adult women diagnosed with acquired, generalized HSDD. The drug has not been evaluated in pediatric populations. No dose has been established, no safety data exist, and the pharmacological target of the drug, central melanocortin receptor activation affecting sexual desire, has no therapeutic rationale in a prepubertal child.

If a caregiver has found this medication in a household or has questions about accidental pediatric exposure, the right first call is Poison Control at 1-800-222-1222 or a pediatric emergency department, not an online guide.

This article exists to explain the clinical reasoning clearly so that caregivers, parents, and family members who encounter Vyleesi in a household understand exactly why this drug must be kept out of reach of children, what the risks of accidental exposure are, and how the drug works in adult women for context.

What Bremelanotide Is and How It Works in Adult Women

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It acts primarily at the MC3R and MC4R receptors in the central nervous system to modulate pathways involved in sexual desire. Unlike estrogen or testosterone, it does not act on sex steroid receptors. Its effect is specifically on central dopaminergic and serotonergic circuits that regulate motivation and arousal.

The RECONNECT Trials

The clinical evidence base for bremelanotide rests on two Phase 3 trials, RECONNECT Study 1 and RECONNECT Study 2, which enrolled a combined 1,247 premenopausal women with diagnosed HSDD. In those trials, women using bremelanotide 1.75 mg subcutaneously 45 minutes before anticipated sexual activity reported a statistically significant increase in satisfying sexual events and a decrease in distress related to low desire compared with placebo. Every participant was an adult premenopausal woman. No data from those trials, or from any subsequent study, applies to children.

Why the Mechanism Is Irrelevant Before Puberty

Hypoactive sexual desire disorder is, by clinical definition, a disorder of adult sexual function. The DSM-5 diagnostic criteria for HSDD require persistent or recurrent deficient sexual desire causing marked distress in an individual, a framework that applies to adults. Prepubertal children do not have a developed hypothalamic-pituitary-gonadal axis driving adult-pattern sexual desire. Melanocortin receptor pathways that bremelanotide targets are also involved in energy homeostasis, cardiovascular regulation, and stress response. Stimulating those pathways in a developing child would carry unpredictable risks that have never been characterised in research.

Pharmacokinetics in Adult Women (and Why Pediatric Extrapolation Fails)

Understanding how the drug behaves in adult women helps explain why extrapolating any dose to a child is not clinically safe.

Absorption and Peak Concentration

After a single 1.75 mg subcutaneous dose, bremelanotide reaches peak plasma concentration (Cmax) in approximately 45 minutes. In the RECONNECT trials, this timing was calibrated to adult body weight and adult renal and hepatic clearance rates. Children have substantially different body surface area, renal clearance, and hepatic enzyme activity compared with adult women. Standard pediatric pharmacokinetic adjustments have not been calculated for bremelanotide because no such study has been conducted or approved.

Blood Pressure Effects

One of the most clinically significant safety signals in adult women is a transient increase in blood pressure after each dose, with mean increases of approximately 2 mmHg for diastolic and systolic pressure occurring within the first 12 hours. The FDA label carries a specific warning that women with cardiovascular disease should not use bremelanotide. In a child, whose cardiovascular physiology differs markedly from an adult's, this pressor effect is entirely unstudied and could pose a disproportionate risk.

Nausea as a Dose-Limiting Effect

In clinical trials, 40% of adult women in the bremelanotide arm reported nausea, making it the most common adverse event. Some women required antiemetic pretreatment. The tolerability and management of this side effect in a child has no evidence base whatsoever.

Renal Impairment Considerations

Bremelanotide area under the curve increases by approximately 78% in adults with severe renal impairment. Pediatric renal function varies by age and developmental stage in ways that make drug exposure in young children unpredictable without specific studies. This is another reason why no responsible prescriber would consider off-label use in a child.

FDA Approval Scope and Regulatory Status

The FDA granted approval for bremelanotide on June 21, 2019. The approved indication is narrow:

• Population: Premenopausal adult women
• Diagnosis: Acquired, generalized hypoactive sexual desire disorder (HSDD)
• Route: Subcutaneous self-injection (abdomen, thigh, or upper arm)
• Dose: 1.75 mg no more than once per 24-hour period

There is no pediatric labeling supplement. The FDA has not requested or received pediatric data under the Best Pharmaceuticals for Children Act or the Pediatric Research Equity Act for this drug, because there is no plausible pediatric indication.

The WomanRx clinical team has developed the following framework for household caregivers to assess risk and take action if bremelanotide is present in a home with children.

The Vyleesi Household Safety Framework for Caregivers

| Situation | Recommended Action | |---|---| | Child has not been exposed; drug is in home | Store in locked cabinet away from children; treat as any prescription medication | | Possible accidental exposure, no symptoms | Call Poison Control: 1-800-222-1222 immediately | | Child has nausea, flushing, or changes in alertness after possible exposure | Go to the nearest pediatric emergency department now | | Caregiver is wondering about therapeutic use in a child | There is no therapeutic use. Speak with a pediatric endocrinologist about the underlying concern | | Household member is prescribed Vyleesi | They should self-administer in private; never delegate injection to someone else or allow access by children |

Life-Stage Context: Who Bremelanotide Is Actually Approved For

Because this site covers women across every life stage, it is worth being precise about which women may benefit from bremelanotide, because it is a genuinely narrow population.

Reproductive-Age Premenopausal Women (Approximately 18 to 45 Years)

This is the only approved population. The ACOG Committee Opinion on Female Sexual Dysfunction notes that HSDD is the most common female sexual dysfunction, affecting approximately 10% of premenopausal women when the distress criterion is applied. Bremelanotide is one of only two FDA-approved pharmacologic options for this condition in premenopausal women; the other is flibanserin (Addyi).

Perimenopausal and Postmenopausal Women

Bremelanotide is not approved for postmenopausal women. The RECONNECT trials did not include postmenopausal participants. Whether the drug is effective or safe in women with declining estrogen and testosterone from menopause has not been established. Postmenopausal women with HSDD are typically managed through different pathways, including genitourinary syndrome of menopause (GSM) treatment, systemic hormone therapy, or testosterone therapy used off-label. The Menopause Society (NAMS) position statement on sexual health does not list bremelanotide among recommended options for postmenopausal HSDD.

Women With PCOS

Women with polycystic ovary syndrome may experience altered sexual desire due to androgen excess, insulin resistance, or the psychological burden of the condition. There is no specific bremelanotide trial in women with PCOS, and the interaction between elevated androgens and melanocortin receptor agonism has not been characterised.

Adolescents (12 to 17 Years)

There are no studies, no labeling, and no approved use in adolescents. HSDD as a clinical entity in adolescents is not well-established in the literature, and management of sexual health concerns in this group falls outside the scope of bremelanotide entirely.

Pregnancy and Lactation: A Required Safety Section

For any woman of reproductive age who is prescribed bremelanotide, pregnancy and lactation safety information is not optional.

Pregnancy

Bremelanotide is contraindicated in pregnancy. Animal reproductive studies showed reduced fertility, fetal growth restriction, and developmental toxicity at doses producing exposures similar to the human therapeutic dose. Human pregnancy data are limited, but the FDA label is unambiguous: discontinue bremelanotide as soon as pregnancy is confirmed.

Women who are not using reliable contraception should not be prescribed bremelanotide. The prescribing clinician should document contraception status before initiating the drug. If a woman becomes pregnant while using bremelanotide, she should contact her OB-GYN immediately and report the exposure to the Vyleesi pregnancy exposure registry (1-833-384-7283).

Lactation

Bremelanotide transfer into human breast milk has not been studied. The drug is a peptide with a molecular weight of approximately 1,025 Da, which may limit oral bioavailability in a nursing infant if transfer does occur, but this has not been confirmed. The FDA label advises that breastfeeding women should pump and discard milk for 24 hours after a dose. Women who are actively breastfeeding should weigh this inconvenience against the limited therapeutic benefit and discuss the decision with their prescriber.

Contraception Requirement

Any premenopausal woman using bremelanotide who does not wish to become pregnant should use a reliable contraceptive method. This is not a drug interaction concern but a precautionary standard given the developmental toxicity signals in animal data.

Who This Drug Is Right For, and Who It Is Not

Right For

• Premenopausal adult women 18 or older with a clinical diagnosis of acquired, generalized HSDD
• Women whose low desire developed after a period of normal desire (acquired), affects all partners and all contexts (generalized), and causes personal distress
• Women who have been evaluated for and are not primarily experiencing desire loss due to a relationship problem, medication side effect, or untreated medical condition
• Women with no significant cardiovascular disease or uncontrolled hypertension

Not Right For

• Girls under 12: no indication, no data, no safe dose
• Adolescents under 18: no approval, no data
• Postmenopausal women: outside the approved population
• Pregnant women: contraindicated
• Women with uncontrolled hypertension or known cardiovascular disease: specific FDA warning
• Women who have used more than eight doses in the past 30 days or more than one dose in 24 hours: exceeds recommended frequency

Accidental Pediatric Exposure: What Caregivers Should Know

Accidental ingestion or injection of adult medications by children is a genuine public health concern. The CDC estimates that approximately 50,000 emergency department visits per year in the US involve children under 6 who have accessed adult prescription medications.

Bremelanotide is supplied as a pre-filled autoinjector, similar in appearance to some other injectable medications. A child who accidentally triggers an autoinjector would receive the full adult 1.75 mg dose subcutaneously. The anticipated effects in a child are unknown but could include the following based on the adult pharmacology:

• Nausea and vomiting (most likely, given 40% incidence even in adults)
• Flushing and skin hyperpigmentation (via MC1R activation)
• Transient blood pressure increase
• Fatigue or drowsiness
• Unpredictable central nervous system effects given differences in pediatric CNS development

None of these effects have been characterised in children. A caregiver who suspects a child has received any amount of bremelanotide should contact Poison Control immediately at 1-800-222-1222 and follow their guidance, which may include emergency department evaluation.

Safe Storage

All autoinjector medications, including bremelanotide, should be stored:

• In a locked cabinet or box, out of reach and out of sight of children
• At room temperature (68 to 77 degrees Fahrenheit) away from moisture
• In the original child-resistant packaging until use
• Away from other household injectable medications to prevent confusion

The Evidence Gap: What We Do Not Know

Bremelanotide was approved based on two trials in a fairly narrow adult population. The evidence gap for populations outside that group is substantial, and caregivers and patients deserve honesty about this.

Women of color were underrepresented in the RECONNECT trials, which limits the generalisability of efficacy and safety data even within the approved population. Women with comorbid depression, thyroid disorders (including postpartum thyroiditis), or chronic pain conditions were not well-studied. The interaction of bremelanotide with hormonal contraceptives was not fully characterised in the trial program.

For children and adolescents, the evidence gap is not partial. It is total. There are no published pharmacokinetic, pharmacodynamic, safety, or efficacy data in any pediatric female population. Any claim that a dose could be calculated or that use in a child might be acceptable is not supported by any published science.

A Note to Caregivers Who Have Questions About a Child's Sexual Development

If a caregiver has arrived at this page because they are concerned about a child's sexual development, precocious puberty, or related hormonal issues, bremelanotide is not the answer to any of those concerns. Those concerns belong in a conversation with a pediatric endocrinologist.

Precocious puberty in girls (onset of breast development before age 8) is evaluated and managed through entirely different pharmacological pathways, primarily GnRH analogues such as leuprolide, not melanocortin agonists. A pediatric endocrinologist can order the appropriate hormonal workup and discuss treatment options that are actually studied and approved in children.

As WomanRx reviewer Elena Vasquez, MD, notes: "When a caregiver asks about Vyleesi in a child, the most important clinical job is to understand what they are really asking. Sometimes it is an accidental exposure question, which is a Poison Control call. Sometimes it is a deeper concern about the child's development or hormonal health, and that concern deserves a proper pediatric referral, not a drug that was never designed or studied for anyone under 18."

Frequently Asked Questions